We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IFL:ASXInsignia Financial Ltd Analysis

Data as of 2026-05-18 - not real-time

A$4.80

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Insignia Financial (IFL) is trading near its recent support of $4.75 and resistance of $4.80, with the 20‑day SMA ($4.78) sitting just above the 50‑day SMA ($4.72) and the 200‑day SMA ($4.58), indicating a short‑term bullish alignment. The RSI of 68.5 suggests momentum is strong but not yet overbought, while the MACD histogram is slightly negative, hinting at a potential near‑term pull‑back. Fundamentally, the company posts a 7.8% revenue growth year‑over‑year and a healthy gross margin of 47%, yet its trailing PE of 28.2 is well above the industry average of 16.7, signaling current overvaluation; the forward PE of 11.7 narrows this gap as earnings are expected to accelerate. Debt remains sizable at a debt‑to‑equity of 47.9% and free cash flow is negative, which tempers the optimism from operating margins of 21% and a ROE of only 5.4%.
The decisive catalyst is the court‑approved takeover by Daintree BidCo offering $4.80 cash per share, effectively locking in the current price and ending public trading as of April 28 2026. With the market sentiment reflected in an “Extreme Greed” reading (89.6) and a low beta (~0.19), upside potential is limited, but the cash‑out deal removes execution risk and provides a clear, albeit modest, return to shareholders.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Takeover cash offer of $4.80 per share
  • Technical support at $4.75 and resistance at $4.80
  • Limited upside due to deal completion

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Deal certainty after court approval
  • Cash distribution eliminates valuation upside
  • Negative free cash flow and moderate debt profile

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Company will be taken private and delisted
  • No dividend and low ROE limit long‑term returns
  • Post‑deal lack of tradable equity eliminates holding value

Key Metrics & Analysis

Financial Health

Revenue Growth7.80%
Profit Margin6.80%
P/E Ratio28.2
ROE5.36%
ROA6.03%
Debt/Equity47.87
P/B Ratio1.5
Op. Cash FlowA$286.2M
Free Cash FlowA$-52987500
Industry P/E16.7

Technical Analysis

TrendBullish
RSI68.5
SupportA$4.75
ResistanceA$4.80
MA 20A$4.78
MA 50A$4.72
MA 200A$4.58
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61

Valuation

Target PriceA$4.80
GradeFair
TypeBlend

Risk Assessment

Beta0.19
Volatility4.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.